Virtu Financial LLC lessened its holdings in shares of Icon Plc (NASDAQ:ICLR) by 16.0% during the 3rd quarter, HoldingsChannel reports. The firm owned 2,533 shares of the medical research company’s stock after selling 481 shares during the period. Virtu Financial LLC’s holdings in Icon were worth $389,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of ICLR. Massachusetts Financial Services Co. MA raised its holdings in Icon by 12.9% in the third quarter. Massachusetts Financial Services Co. MA now owns 1,070,319 shares of the medical research company’s stock valued at $164,561,000 after acquiring an additional 121,970 shares in the last quarter. Dorsey Wright & Associates acquired a new stake in Icon in the third quarter valued at approximately $6,644,000. Private Advisor Group LLC raised its holdings in Icon by 186.6% in the second quarter. Private Advisor Group LLC now owns 8,404 shares of the medical research company’s stock valued at $1,111,000 after acquiring an additional 5,472 shares in the last quarter. Atria Investments LLC raised its holdings in Icon by 18.5% in the third quarter. Atria Investments LLC now owns 6,556 shares of the medical research company’s stock valued at $1,008,000 after acquiring an additional 1,024 shares in the last quarter. Finally, Envestnet Asset Management Inc. raised its holdings in Icon by 376.6% in the second quarter. Envestnet Asset Management Inc. now owns 88,669 shares of the medical research company’s stock valued at $11,751,000 after acquiring an additional 70,064 shares in the last quarter. 86.54% of the stock is currently owned by institutional investors and hedge funds.

ICLR has been the topic of several analyst reports. BidaskClub cut shares of Icon from a “strong-buy” rating to a “buy” rating in a report on Tuesday, November 20th. UBS Group initiated coverage on shares of Icon in a report on Tuesday, October 9th. They issued a “sell” rating and a $145.00 target price on the stock. Zacks Investment Research cut shares of Icon from a “hold” rating to a “sell” rating in a report on Wednesday, October 24th. KeyCorp raised their target price on shares of Icon from $152.00 to $157.00 and gave the company an “overweight” rating in a report on Tuesday, September 11th. Finally, Robert W. Baird raised their target price on shares of Icon from $154.00 to $157.00 and gave the company an “outperform” rating in a report on Tuesday, September 11th. Two analysts have rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Icon presently has an average rating of “Buy” and an average target price of $148.00.

Shares of Icon stock opened at $138.11 on Thursday. The company has a market capitalization of $7.48 billion, a price-to-earnings ratio of 25.62, a P/E/G ratio of 1.98 and a beta of 0.55. Icon Plc has a 52 week low of $101.22 and a 52 week high of $155.33. The company has a debt-to-equity ratio of 0.26, a quick ratio of 2.17 and a current ratio of 2.17.

Icon (NASDAQ:ICLR) last announced its quarterly earnings results on Wednesday, October 24th. The medical research company reported $1.54 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $1.54. The company had revenue of $655.02 million for the quarter, compared to analyst estimates of $654.66 million. Icon had a net margin of 12.88% and a return on equity of 26.08%. Analysts anticipate that Icon Plc will post 6.08 EPS for the current fiscal year.

WARNING: “Virtu Financial LLC Trims Stake in Icon Plc (ICLR)” was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://theolympiareport.com/2018/12/13/virtu-financial-llc-trims-stake-in-icon-plc-iclr.html.

Icon Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

See Also: What is a Futures Contract?

Want to see what other hedge funds are holding ICLR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Icon Plc (NASDAQ:ICLR).

Institutional Ownership by Quarter for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.